Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Baxter International Inc.    BAX

BAXTER INTERNATIONAL INC.

(BAX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Baxter Adds Finomel With Fish Oil to Ready-to-use Parenteral Nutrition Portfolio: Baxter International Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:57pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Pharma Business Daily -- Baxter International Inc. (NYSE:BAX), a global leader in clinical nutrition, announced the European launch of Finomel, a ready-to-use triple-chamber bag for parenteral nutrition (PN). Finomel expands the company’s portfolio of leading premixed PN formulations and offers healthcare providers with additional options to meet adult patients’ diverse nutritional needs.

For clinicians who prefer to prescribe PN products containing fish oil, Finomel delivers 7.6g/L of fish oil, rich in omega-3 fatty acids, which is at least 33 percent more than any other fish oil-containing premixed PN product currently on the market.1,2,3 Finomel contains a four-oil lipid emulsion comprised of soybean oil, medium-chain triglycerides, olive and fish oil.

“Our investment in new formulations like Finomel demonstrates our commitment to ensure healthcare providers have access to products that address a wide range of nutritional needs, including malnourished patients in the ICU and with other critical illnesses,” said Jorge Vasseur, general manager of Baxter’s Clinical Nutrition business. “Finomel joins our line of industry-leading Olimel PN formulations to strengthen one of the broadest, most complete ready-to-use PN portfolios available to clinicians.”

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, NewsRx Pharma Business Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC.
08:17aBAXTER INTERNATIONAL : Bis Henderson recruits senior practitioner to Executive S..
AQ
08/15BAXTER INTERNATIONAL : and COSMED Announce Partnership to Bring Next-generation ..
BU
08/14BAXTER INTERNATIONAL : to Present at the Morgan Stanley 17th Annual Global Healt..
BU
08/13BAXTER INTERNATIONAL : to Present at the 2019 Wells Fargo Healthcare Conference
BU
08/13BAXTER INTERNATIONAL : Georgia-based Hamilton Health Care System First in U.S. t..
BU
08/05BAXTER INTERNATIONAL : HHS - Trump Administration Officials Visit Bloomington, I..
AQ
07/30BAXTER INTERNATIONAL : Management's Discussion and Analysis of Financial Conditi..
AQ
07/30BAXTER INTERNATIONAL : Recognized With Highest Achievement on 2019 Diversity Bes..
BU
07/30BAXTER INTERNATIONAL : Supports Add-on Payment in Proposed ESRD Payment Rule to ..
BU
07/29BAXTER INTERNATIONAL : Launches PrisMax in U.S. to Maximize Care for Critically ..
BU
More news
Financials (USD)
Sales 2019 11 300 M
EBIT 2019 2 050 M
Net income 2019 1 575 M
Debt 2019 1 271 M
Yield 2019 0,95%
P/E ratio 2019 29,4x
P/E ratio 2020 24,6x
EV / Sales2019 4,08x
EV / Sales2020 3,91x
Capitalization 44 863 M
Chart BAXTER INTERNATIONAL INC.
Duration : Period :
Baxter International Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAXTER INTERNATIONAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 91,44  $
Last Close Price 87,87  $
Spread / Highest target 19,5%
Spread / Average Target 4,07%
Spread / Lowest Target -21,5%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Executive Vice President
Paul E. Martin Chief Information Officer & Vice President
Sumant Ramachandra Senior VP, Chief Science & Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL INC.33.50%44 863
MEDTRONIC PLC14.53%139 719
HOYA CORPORATION31.33%30 013
ZIMMER BIOMET HOLDINGS33.59%28 448
TERUMO CORP-46.18%22 806
DEXCOM, INC.36.55%14 917